Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2008 1
2010 2
2011 1
2012 1
2014 1
2015 1
2016 3
2017 3
2018 3
2019 3
2020 5
2021 4
2022 3
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
Wray S, Then Bergh F, Wundes A, Arnold DL, Drulovic J, Jasinska E, Bowen JD, Negroski D, Naismith RT, Hunter SF, Gudesblatt M, Chen H, Lyons J, Shankar SL, Kapadia S, Mendoza JP, Singer BA. Wray S, et al. Among authors: wundes a. Adv Ther. 2022 Apr;39(4):1810-1831. doi: 10.1007/s12325-022-02068-7. Epub 2022 Feb 24. Adv Ther. 2022. PMID: 35211872 Free PMC article. Clinical Trial.
Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
Naismith RT, Wundes A, Ziemssen T, Jasinska E, Freedman MS, Lembo AJ, Selmaj K, Bidollari I, Chen H, Hanna J, Leigh-Pemberton R, Lopez-Bresnahan M, Lyons J, Miller C, Rezendes D, Wolinsky JS; EVOLVE-MS-2 Study Group. Naismith RT, et al. Among authors: wundes a. CNS Drugs. 2020 Feb;34(2):185-196. doi: 10.1007/s40263-020-00700-0. CNS Drugs. 2020. PMID: 31953790 Free PMC article. Clinical Trial.
Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Naismith RT, Wolinsky JS, Wundes A, LaGanke C, Arnold DL, Obradovic D, Freedman MS, Gudesblatt M, Ziemssen T, Kandinov B, Bidollari I, Lopez-Bresnahan M, Nangia N, Rezendes D, Yang L, Chen H, Liu S, Hanna J, Miller C, Leigh-Pemberton R. Naismith RT, et al. Among authors: wundes a. Mult Scler. 2020 Nov;26(13):1729-1739. doi: 10.1177/1352458519881761. Epub 2019 Nov 4. Mult Scler. 2020. PMID: 31680631 Free PMC article.
Inflammatory colitis associated with Teriflunomide.
Esfahani NZ, von Geldern G, Romba MC, Parikh DA, Wundes A. Esfahani NZ, et al. Among authors: wundes a. Mult Scler Relat Disord. 2020 Nov;46:102480. doi: 10.1016/j.msard.2020.102480. Epub 2020 Sep 8. Mult Scler Relat Disord. 2020. PMID: 32942118
COVID-19 in MS: Initial observations from the Pacific Northwest.
Bowen JD, Brink J, Brown TR, Lucassen EB, Smoot K, Wundes A, Repovic P. Bowen JD, et al. Among authors: wundes a. Neurol Neuroimmunol Neuroinflamm. 2020 May 26;7(5):e783. doi: 10.1212/NXI.0000000000000783. Print 2020 Sep 3. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32457226 Free PMC article. No abstract available.
The validity, responsiveness, and score interpretation of the PROMISnq Physical Function - Multiple Sclerosis 15a short form in multiple sclerosis.
Kamudoni P, Amtmann D, Johns J, Cook KF, Salem R, Salek S, Raab J, Middleton R, Repovic P, Alschuler KN, von Geldern G, Wundes A, Barrett A, Olayinka-Amao O, Henke C. Kamudoni P, et al. Among authors: wundes a. Mult Scler Relat Disord. 2022 Jun;62:103753. doi: 10.1016/j.msard.2022.103753. Epub 2022 Mar 21. Mult Scler Relat Disord. 2022. PMID: 35598408 Free article.
27 results